This test is designed to detect carriers of phenylketonuria. Phenylketonuria (PKU) is an autosomal recessive disorder resulting from faulty metabolism of the amino acid, phenylalanine. In individuals with untreated PKU, dietary intake of phenylalanine can lead to profound intellectual disability, behavioral issues, epilepsy, hypopigmentation, and a musty body odor.

This test is designed to detect carriers of phenylketonuria. Phenylketonuria (PKU) is an autosomal recessive disorder resulting from faulty metabolism of the amino acid, phenylalanine. In individuals with untreated PKU, dietary intake of phenylalanine can lead to profound intellectual disability, behavioral issues, epilepsy, hypopigmentation, and a musty body odor. Additionally, women with PKU are at risk for having children with various birth defects due to exposure of the baby to high phenylalanine levels from maternal plasma. Newborn screening and early initiation of treatment, including lifelong dietary restriction of phenylalanine, can significantly improve disease prognosis. PKU (MIM 261600) is caused by pathogenic variants in the PAH gene (NM_000277). Individuals with a heterozygous pathogenic PAH variant are carriers for PKU and are at risk of having a child with this disorder. If both reproductive partners are PKU carriers, the risk for PKU in their children is 25%. The prevalence of PKU varies in different populations and is more common in individuals of Turkish, Irish, northern European, and East Asian ancestry. This test is intended for pre/post-conception carrier screening and is not intended for diagnostic testing.

Gene(s)

PAH

MIM

261600

Methodology

Billing

CPT Code(s)
81406 x 1

Ordering

Test Code
6007

Additional Test Codes
Please call for pricing

Turnaround Time
Typically within 2 weeks from receipt of a sample in the laboratory.

Specimens
Whole blood: purple-top (EDTA) tube, minimum of 3 ml
Genomic DNA: minimum of 3 µg (at a concentration of at least 30 ng/µl)

Shipping
Ship all specimen types at room temperature by overnight courier. Do not freeze.

The American Medical Association (AMA) Current Procedural Terminology (CPT) codes published by HNL Lab Medicine are guidelines and are intended for informational purposes only. CPT coding is the exclusive responsibility of the billing entity. HNL Lab Medicine strongly recommends confirmation of CPT codes with third-party payors and/or the AMA. We assume no responsibility for billing errors due to reliance upon CPT codes provided by HNL Lab Medicine.

News

October 28, 2022

Non-Hodgkin Lymphoma FISH Panel Now Available

B-cell lymphoma is a large group of heterogenous disorders and comprises a majority of non-Hodgkin lymphomas.
Read More
October 20, 2022

Genetic testing for Familial Transthyretin Amyloidosis (TTR) NOW AVAILABLE In-House

Hereditary amyloidosis is a life-threatening disorder that can lead to peripheral neuropathy and heart failure.
Read More
August 08, 2022

Familial hypercholesterolemia (FH)

Familial hypercholesterolemia (FH) is a genetic disorder that increases the likelihood of having coronary heart disease at a younger age. Learn about how to determine if you have hypercholesterolemia and what actions you can take to create better outcomes!

Read More
April 11, 2022

Genome Sequencing: A Vital Tool Used in Identifying and Tracking New COVID-19 Variants

Genome sequencing is reading or decoding the complete genetic information i.e. “Genome” of an organism that is encrypted in the form of a very long string called DNA made up of 4 letters, A, T, G, and C. The genome of an organism essentially determines their physical characteristics and ...
Read More
March 03, 2022

The Effect of Genetics on Individual Heart Health: Early Identification of FH Variations to Optimize Treatment

Test must be ordered by a Physician.

Familial hypercholesterolemia (FH) is a genetic disorder that is characterized by abnormally high blood levels of low-density lipoprotein (LDL) cholesterol, sometimes referred to as "bad cholesterol". This condition affects an estimated 1 in 250 people, and increases the likelihood of developing cardiovascular disease. In fact, FH is estimated to be the cause of 2-3% of heart attacks in individuals younger than age 60.

Read More